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Background: Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to
have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological
disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The
study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism
symptomatology in children with autism and a history of developmental regression.
Methods: Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children
completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were
obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation.
Results: Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the
expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth
factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and α-2 macroglobulin (α-2 M), was also
significantly lower (P = 0.028) while the mature BDNF/α-2 M ratio revealed no difference following treatment. Only the
chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in
CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-α, CD40L, IL-6, IFN-γ and IL-1β when
pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were
seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline.
Conclusions: Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8)
in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth
factors. However, in this small group of children, no clinical improvements were observed during or after the six
months of minocycline administration.
Trial registration: NCT00409747
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Autism is a neurodevelopmental disorder that results in
abnormalities of social communication and is associated
with rigid and repetitive behaviors [1]. The spectrum of
clinical features, including the onset and progression of
neurobehavioral abnormalities, is quite heterogeneous. A
subset of children with autism experiences a loss of* Correspondence: cpardov1@jhmi.edu
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reproduction in any medium, provided the orlanguage and social skills (so-called developmental regres-
sion). In this subset with regression, an accelerated dis-
turbance of the neurobiological developmental trajectories
may be taking place [2,3]. Previous neuropathologic and
structural studies in patients with autism suggested the
presence of ongoing innate neuroinflammatory mecha-
nisms characterized by activation of microglia and
astroglia together with abnormalities in cytokines and
chemokines [4-7]. These findings highlighted the role of
innate neuroimmune mechanisms and their potential to
contribute to the establishment and progression oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neuronal function, neuronal-glial interaction, and synaptic
plasticity. Under normal conditions, microglia are integral
components of brain homeostasis involved in synaptic plas-
ticity, neurogenesis, axon guidance, and cortical organization
[8-11]. However, in response to direct injury or to neuronal
dysfunction, activated microglia can elaborate numerous cy-
tokines and cytotoxins that can further damage neurons
[12]. In autism, microglial activation has been shown to
occur in regions of the central nervous system such as the
cerebellum and the frontal and anterior cingular cortices
[6,7], areas of the brain involved in the neurobehavioral ab-
normalities that characterize this disorder [13].
Minocycline is a semisynthetic derivative of tetracyc-
line that readily crosses the blood brain barrier. In
addition to being an antibacterial agent, it has direct
neuroprotective effects [14] as well as anti-inflammatory
properties. It also has a proven tolerability and safety
profile for clinical use [15]. In recent years, it has be-
come one of the most investigated therapeutic candi-
dates for modulation of microglial activation and innate
neuroinflammatory pathways in neurological disorders,
although contradictory results have been obtained in re-
cent clinical trials [16,17]. The exact mechanism by
which minocycline modifies inflammation is not fully
understood. The drug likely targets multiple inflammatory
pathways via complex interactions with proteins integral
to the inflammatory cascade [18]. This independent mod-
ulatory function on neuroinflammation is, at least in part,
mediated via microglial inhibition [19].
The effect of minocycline on neuroinflammation and its
potential role as a neuroprotectant has been evaluated in ani-
mal models of stroke, neurodegeneration, neuroimmunity,
and neuroinfection [20]. Most of these studies showed that
minocycline decreases microglial activation, modulates path-
ways involved in neuroinflammation, such as cytokine and
chemokine networks (for example, interleukin-6 (IL-6), inter-
leukin 1β (IL-1β) and tumor necrosis α (TNFα)), and re-
duces the activity of selected metalloproteinases (MMPs)
[21,22]. The neuroprotective role of minocycline in these
models has been attributed to anti-apoptotic and
anti-oxidant properties [23]. Interestingly, minocycline
appeared to regulate behavior and reduced the impact of
stress on neuronal activation and working memory by
modulation of microglial activation in a model of stress
[24]. Based on the potential anti-inflammatory and
neuroprotective properties shown by minocycline in ani-
mal models, therapeutic trials in humans have been car-
ried out in a number of neuroinflammatory diseases such
as multiple sclerosis [25] and neurodegenerative [26-28],
and cerebrovascular diseases [29]. Recent studies in a mouse
model of fragile X (Fmr1 KO), a neurodevelopmental dis-
order that shares some neurological and neurobiological fea-
tures with autism, demonstrated that minocycline was ableto promote dendritic spine maturation via inhibitory effects
on MMP-9 expression and that these effects were accom-
panied by improvements in the behavioral performance of
treated animals [30]. Furthermore, an open-label add-on
treatment trial with minocycline in patients with fragile X
showed behavioral benefits without major side effects [31].
On the other hand, while amyotrophic lateral sclerosis
(ALS) studies in animal models showed great promise [32],
as did the results of phase I and II clinical trials [16,17] a re-
cently completed phase III randomized clinical trial showed
adverse effects of the medication [17] in this disorder.
The potential usefulness of minocycline in a variety
of neurological disorders involving neuroinflammation
coupled with the above findings suggestive of innate
neuroinflammatory pathways in autism, led to the hy-
pothesis that minocycline could be useful in the treat-
ment of patients that exhibit the regressive subtype of
autism. Accordingly, we designed an open-label pilot
trial study to evaluate the effects of minocycline on
markers of neuroinflammation and to assess its impact
on the clinical profile of children with regressive
autism.
Methods
Study design and subjects
An open-label pilot trial of minocycline therapy for chil-
dren with autism and a history of regression was ap-
proved by the National Institutes of Health (NIH)
Institutional Review Board (NCT00409747). Consent for
participating in the pilot trial was obtained from the par-
ents or legal guardian. Minocycline dosage was calcu-
lated for each subject at 1.4 mg/kg per day. This dose
was based on the Bonelli et al. 2004 study of minocycline
in Huntington’s Disease, which used 100 mg/day in adult
subjects [33]. Vitamin B6 at a dose of 0.6 mg/kg twice
daily was given in conjunction with minocycline adminis-
tration to mitigate the potential for vestibular side effects.
Subjects were referred and evaluated at the Intramural
Autism Research Program of the National Institute of
Mental Health, Bethesda, Maryland. Children were eli-
gible for inclusion if they were between three and twelve
years of age, met research criteria for a diagnosis of aut-
ism, had a history of developmental regression, and were
stable on all behavioral and/or medical therapies. Autism
diagnoses were made using the Autism Diagnostic Inter-
view - Revised (ADI-R) [34] or a Toddler version, the
Autism Diagnostic Observation Schedule [35], and clin-
ical judgment based on DSM-IV criteria for autistic dis-
order. The diagnostic evaluations also included cognitive
testing (described below), and information from the
Vineland Adaptive Behavior Scales, Second Edition
(VABS) [36]. Regression was defined as language loss
(loss of at least three spontaneously meaningful words)
and/or nonverbal communication/social loss (loss of
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gression histories were confirmed by the ADI-R and a
modified Regression Validation Interview [37].
Subjects were excluded for known genetic defects,
based on medical records or clinical genetics testing,
prematurity of less than 32 weeks gestation or small for
gestational age status, serious neurologic disorders (for
example, cerebral palsy or uncontrolled epilepsy), evi-
dence of renal insufficiency, hepatic disease or auto-
immune disorder, or presence of a first degree relative
with systemic lupus erythematous. Patients were also ex-
cluded if they were taking any medications that were
contraindicated with either minocycline or vitamin B6.
Eleven children (9 boys, 2 girls; mean age 7.19 years;
range 3 to 12 years) were enrolled in the trial. By clinical
history, loss of social and communication skills had oc-
curred at a mean age of 18.4 months (range 8 to 28 -
months). Ten children completed the six-month open-label
trial; one child dropped out after three months because of
parental concerns about side effects.
Clinical and behavioral assessments were performed at
baseline and at post-treatment during the trial, and data
are presented in Table 1. At baseline, eight participants
were administered the Mullen Scales of Early Learning
[38] and three participants were administered the Differ-
ential Ability Scales Second Edition (DAS-II) [39]. Since
many of the children who were assessed with the Mullen
Scales were out of age range or below the ‘floors’ of the
standard scales, a nonverbal developmental quotient
(NVDQ) was used to describe intellectual functioning.
The NVDQ is the ratio of IQ of age equivalent/chrono-










1 99 F 27 30
2a 64 M 13 60
3 69 M 12 33
4 153 M 19 77
5 91 M 8 58
6 66 M 18 103
7 128 F 15 25
8 112 M 14 33
9 49 M 18 59
10 38 M 22 90
11 83 M 18 32
M± SD 4.6
Effect Size
aDenotes child that discontinued the study at 3 months.
Note: Effect size was calculated for the within-subjects effect using the following fothe test. For the three participants administered the
DAS-II, the nonverbal cognitive score was the standard
score from the nonverbal reasoning domain.
The severity of core autism symptoms was rated at base-
line and monthly intervals using the Clinical Global Im-
pression Severity Scale (CGI-S) [40], and change was
recorded with the CGI-Improvement (CGI-I). In addition,
adaptive functioning was measured using the VABS. Par-
ents were queried about medication side effects at
monthly intervals.
Serum, plasma and cerebrospinal fluid (CSF) samples
were obtained at baseline and following six months of
minocycline administration. CSF was obtained by lum-
bar puncture under fasting conditions, while the child
was sedated with propofol. Venous blood samples were
obtained at the same time as the CSF and aliquots of
both were sent for immediate analysis of routine labora-
tory tests at NIH or stored (−80°C) for research analyses.
Subjects also underwent monthly blood tests for evaluat-
ing potential hematological, metabolic, or hepatic side
effects.
The cytokines TNFα, IFN-γ, IL-1α, IL-1β, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-10, IL-12(p40), IL 12(p70), IL-
13, IL-15, GM-CSF and the chemokines CCL2 (MCP-1),
CCL3 (MIP-1α), CCL5 (Rantes), CXCL8 (IL-8), CCL11
(Eotaxin) and CXCL10 (IP-10) were measured in the
serum and CSF at baseline and after six months treat-
ment with minocycline. Additional assays included com-
parisons of baseline and six months concentrations of
plasma and CSF leptin, CD40 ligand and neurotrophic
factors such as brain neurotrophic growth factor (BDNF),
hepatic growth factor [HGF], and glial derived growthClinical assessment




6 5 55 54
5 4a 68 73a
5 5 45 44
5 5 56 55
3 3 60 56
4 4 70 71
5 5 55 46
5 5 53 56
4 4 66 63
4 3 70 66
5 5 48 57
± 0.8 4.4 ± 0.8 58.7 ± 8.8 58.3 ± 9.3
- −0.3 - −0.1
rmula: ES = (MPost - MBL)/SDBL). CGI, Clinical Global Impression.
Table 2 Reported health problems during minocycline
treatment
Subject URIa GIb Others
1 X Hematuria, weight gain, hyperactivity, urinary
tract infection
2c X Increased aggression and head-banging, c/o
head hurting
3 X Otitis media
4 X Epistaxis, increased sensitivity to lights
5 X X Increased aggression
6 X
7 Teeth staining; increased appetite, aggression
and ritualistic behavior, weight gain, PICA




aURI, Upper respiratory infection symptoms.
bGI, Gastrointestinal symptoms included nausea, vomiting, and/or diarrhea on
at least one occasion.
cSubject withdrew at three months.
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8 and MMP-9) were also measured in plasma.
All analytes were measured by multiplexed bead array
assays (Luminex™) techniques with exception of the pro-
form (pro-BDNF), truncated form (truncated-BDNF)
and mature form of BDNF (mature-BDNF) that were
measured by immunoblot analysis of serum samples
using an antibody that recognized all three isoforms
(Santacruz Biotechnology, Inc., Dallas, Texas, USA, cat#
SC546). The relative presence of the pro-BDNF, truncated-
BDNF and mature-BDNF in serum was determined by
densitometric analysis and its presence was established
as a ratio in which α-2 macroglobulin was used for
normalization. Multiplexed assay kits and beads were
obtained from commercial sources (for example,
BioRad™, Invitrogen™, R&D systems™ and Millipore™)
and procedures followed manufacturers’ recommenda-
tions. Blinded samples were measured in duplicates
and blank values subtracted from all readings. Measure-
ments and data analysis of all assays were performed with
the Luminex-200™ system in combination with
Luminex manager software (Bioplex Manager 5.0, Bio-
Rad, Hercules, CA, USA). Our biomarker quality as-
surance program used standard operating procedures
to review results for unexpected or unacceptable vari-
ance (evidence of bead clumping, coefficients of vari-
ation greater than 20%, unusual distributions of values,
outliers more than 4 SD from the mean).
Statistics
The Mann–Whitney U-test was used to compare pre-
/post-treatment differences in analyte concentrations in




Clinical improvements were negligible, with CGI-S
scores remaining stable and only two of ten children
demonstrating ‘minimal improvement’ on the CGI-I.
The VABS composite scores also showed little or no
change (Table 1). Adverse events reported by parents
(Table 2) included gastrointestinal and upper respiratory
(‘colds’) symptoms (Table 2). Side effects were deemed
problematic for three subjects. One child (subject 7) was
reported to have weight gain, appetite increase, diaper
rash, pica, and concerns about her teeth becoming
discolored (could not differentiate from developmental
defects of enamel). Another child (subject 8) was ob-
served to have persistent, benign hematuria. The third
subject (subject 2), a minimally verbal child, was
reported to have had several episodes of crying and
holding his head, which the mother reported to be con-
sistent with headache. This child was withdrawn fromthe study at three months because of parental concerns
about the adverse events.
Cytokines and Chemokine profiles
There were no significant changes in the quantitative as-
sessment of cytokines and chemokines in both serum
and CSF as measured by multiplexed microbead array
technology (Luminex™). Expression of chemokines, such
as CCL2 (MCP-1) or cytokines such as TNF-α, CD40L,
IL-6, IFN-γ and IL-1β, well recognized immune media-
tors implicated in inflammatory mechanisms, were not
affected in serum or CSF when pre- and post-treatment
levels of these proteins were compared (Table 3). Only
the chemokine CXCL8 (IL-8) in serum was significantly
reduced after treatment (P = 0.047) (Figure 1A); seven of
ten patients had reduction in the serum level of CXCL8
(IL-8) (Figure 1B).
Growth factor profiles
Profiling of BDNF used Luminex™ and immunoblotting
techniques. Immunoblot analysis, which facilitates the as-
sessment of the BDNF isoforms, showed that while the
pro-BDNF, truncated-BDNF and mature-BDNF isoforms
are identified in serum, plasma samples are devoid of the
mature-BDNF form, an observation that reflects the re-
lease of the mature-BDNF form from platelets during
clot formation. Interestingly, similar immunoblot stud-
ies showed that only the truncated-BDNF isoform is
detected in the CSF (Figure 2A), a finding that demon-
strates that only such form is measurable by the
available Luminex or ELISA techniques. Immunoblot
analysis of the BDNF isoforms in serum showed the
Table 3 Treatment effect on cytokines, chemokines,




Z P Z P Z P
TNFα −0.45 0.66 −1.78 0.074
IL-6 −0.36 0.72 −1.75 0.08
CCL2 (MCP-1) −1.78 0.075 −1.27 0.24
CCL3 (MIP-1α) −0.18 0.86 −0.76 0.45
CCL5 (RANTES) −0.73 0.47 0.66 0.61
CXCL8 (IL-8) −0.45 0.66 −1.99 0.047
BDNFb −2.03 0.042 −0.76 0.45
Truncated-BDNF/α-2 Mc −2.19 0.028
Mature-BDNF/α-2 M c −0.87 0.386
CD40L −0.89 0.37 −1.33 0.18
GDNF −0.37 0.71 −1.83 0.07
HGF −2.19 0.028 −1.25 0.21






aSelected analytes, Mann–Whitney U-test.
bQuantified by Luminex technique. In CSF only the truncated-BDNF form
appears to be detectable in immunobotting experiments.
cQuantified by immunoblotting and densitometry analysis. Significance was
calculated based on ratio BDNF isoform/α-2 M.
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tive presence of such isoform was significantly lower
following minocycline treatment at six months (P = 0.028)
(Figure 2B) while the mature-BDNF/α-2 M ratio demon-
strated no difference (P = 0.38) (Figure 2C). Interestingly,
BDNF measured by Luminex™ technique in CSF, (assumed
to be the truncated-BDNF form), showed a significantly
lower concentration post-treatment (P = 0.042) (Figure 2D).Figure 1 CXCL8 (IL-8) Post-treatment trend in serum. (A) Serum levels
minocycline. (P = 0.047). (B) The trend profile of CXCL8 (IL-8) in serum show
while only three of ten (green lines) showed an increase.The plasma BDNF concentration measured by Luminex™
technique, which reflects the presence of pro- and
truncated-BDNF isoforms combined, did not show differ-
ence after treatment (P = 0.45). Contrary to BDNF, the
growth factor HGF, (and ligand for MET), was found
to be significantly increased in the CSF after treatment
(P = 0.028) (Figure 3) but was not significantly different
in serum. The CSF concentration of GDNF showed no
difference after minocycline treatment.
Metalloproteinases
No significant post-treatment changes were seen in the
profiles of MMPs (MMP-1, MMP-3, MMP-7, MMP-8
and MMP-9) in either CSF or plasma, although there
was a trend towards change in plasma MMP7 (P =
0.059) (Figure 4), one of the MMPs that appears to be a
target for minocycline.
Discussion
The trial revealed no significant effects of minocycline
on the profile of immune mediators implicated in in-
flammatory mechanisms in either the serum or CSF of
treated children with the exception of a reduction in the
levels of CXCL8 (IL-8), a chemokine that appears to
have neuroprotective effects [41] and regulates the re-
lease of MMPs [42]. A hypothesized reduction of im-
mune modulators associated with monocyte trafficking
or microglia function such as CCL2 (MCP-1) or certain
MMPs, was not proven by this clinical trial. Concentra-
tions of MMPs in this study were unaffected after treat-
ment with minocycline and only MMP-7 disclosed a
decreasing trend (P = 0.059) while MMP-9, a putative
target of minocycline effect [43], was unchanged after
treatment.
Interestingly, changes in the profiles of some growth fac-
tors suggest that minocycline exerted biological effects
that were not translated into behavioral or neurological
changes. The changes observed in the pre-/post-treatment
profiles of truncated-BDNF isoforms in CSF and bloodof CXCL8 (IL-8) were significantly lower after treatment with
ed a lowering effect of treatment in seven of ten patients (red lines)
Figure 2 Profiles of expression of brain derived neurotrophic factor in serum and cerebrospinal fluid. (A) Immunoblot analysis of brain
derived neurotrophic factor (BDNF) isoforms in serum disclosed the presence of the pro-form (32 kD), truncated-form (28 kD) and mature form
(14 kD) while plasma disclosed mostly the presence of the BDNF pro-form and truncated-form. The truncated-BDNF form was the only isoform
seen in cerebrospinal fluid (CSF). (B)The BDNF truncated-form was significantly decreased after treatment with minocycline (P = 0.028) a trend
that was observed in six of ten patients (red lines). (C) Although the mature form appeared to be decreased after treatment the difference
pre- and post-treatment did not reach significance (P = 0.38). (D) BDNF in CSF measured by multiplexed array technique, which detects mostly
the truncated-BNDF isoform, was significantly lowered after treatment (P = 0.042).
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that higher doses of minocycline could potentially
modulate the proteolytic processing of some neuro-
trophic growth factors. BDNF pro-form and truncated-
form appear to be critical for mechanisms of synapticplasticity. Both forms are not necessarily inactive inter-
mediates in the biosynthesis of BDNF but rather bio-
logically active forms with opposite functions with
respect to the mature-BDNF form that may be involved in
the neurobiological abnormalities that underlie cognitive
Figure 3 The levels of hepatic growth factor (HGF) in cerebrospinal fluid (CSF) were significantly increased following treatment with
minocycline. (P = 0.028).
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the processing of BDNF in autism was demonstrated re-
cently by studies of the fusiform gyrus of the brain of pa-
tients with autism that disclosed abnormal processing of
the pro- and truncated-BDNF forms [48]. HGF acts as the
ligand for cMET, a receptor protein kinase in which the
functional promoter variant of the gene has been impli-
cated as a risk for autism and its social and communica-
tion phenotypes [49,50].
Overall, there were no significant improvements in the
clinical and behavioral measurements of this small group
of children with autism and regressive features during
the six-month treatment period. Two of the younger
children appeared to have minimal improvements on the
CGI. However, objective measures of nonverbal cogni-
tive ability, adaptive behavior and overall autism symp-
toms showed no significant changes during open-label
administration of minocycline.
The lack of a meaningful clinical effect requires us to re-
ject the hypothesis that a daily dose of 1.4 mg/kg of
minocycline will produce improvements in the neurobio-
logical trajectories of individuals with autism. The lack of
clinical and biological effects in our patient population
may reflect: 1) limitations of the study design, includingFigure 4 A post-treatment lowering effect on MMP-7 was observed in
not reach statistical significance. (P = 0.059).wide age range; 2) the complexity of neurobiological
mechanisms involved in autism pathogenesis; 3) the rela-
tively low dose of the medication used in this trial as com-
pared with clinical trials conducted with young adults or
elderly patients; or 4) differences in drug metabolism and
neurobiological effects of the medication in young chil-
dren. While a higher dose might prove useful in changing
the CSF markers of inflammation, it would also be associ-
ated with an increased risk of toxicity. The prominence of
adverse effects in this small sample of young children with
autism suggests that more aggressive treatment regimens
would not be tolerable and might be anticipated to have
an unfavorable risk: benefit ratio.
Conclusions
No clinical improvement was observed after minocycline
treatment in this small pilot open-trial study of chil-
dren with autism and regressive features. Interestingly,
changes in the pre- and post-treatment profiles of
some markers, including BDNF isoforms in CSF and
blood, HGF in CSF, and CXCL8 (IL-8) in serum, sug-
gest that minocycline might have effects in the CNS by
modulating the production of neurotrophic growth
factors.seven of ten patients (red lines), but despite this trend it did
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